Revista: | Archives of clinical psychiatry |
Base de datos: | PERIÓDICA |
Número de sistema: | 000431176 |
Autores: | Junho, Bruno Terra1 Oliveira, Victor Fernandes de2 |
Instituciones: | 1Faculdade de Ciencias Medicas de Minas Gerais, Departamento de Saude Mental, Belo Horizonte, Minas Gerais. Brasil 2Universidade de Sao Paulo, Escola de Ciencias Farmaceuticas, Sao Paulo. Brasil |
Año: | 2019 |
Periodo: | Nov-Dic |
Volumen: | 46 |
Número: | 6 |
Paginación: | 165-168 |
País: | Brasil |
Idioma: | Inglés |
Tipo de documento: | Artículo |
Enfoque: | Analítico, descriptivo |
Resumen en inglés | Schizophrenia is a complex and chronic psychiatric disorder. In recent years, studies have found glutamatergic system participation in its etiopathogenesis, especially through aberrant NMDA receptors functioning. Thus, drugs that modulate this activity, as amantadine and memantine, could theoretically be used in its treatment. To perform a systematic literature review about memantine and amantadine use as adjunct in schizophrenia treatment. Methods A systematic review of papers published in English indexed in the electronic database PubMed ® using the terms “memantine”, “amantadine” and “schizophrenia” published until October 2016. Results We found 144 studies, 8 selected for analysis due to meet the objectives of this review. Some of these have shown benefits from such drug use, especially in symptoms measured by PANSS and its subdivisions, while others do not. Discussion: The data in the literature about these drugs use for schizophrenia treatment is still limited and have great heterogeneity. Thus, assay with greater robustness are needed to assess real benefits of these drugs as adjuvant therapy |
Disciplinas: | Medicina |
Palabras clave: | Psiquiatría, Farmacología, Esquizofrenia, Neurofisiología, Etiopatogénesis, Memantina, Amantadina |
Keyword: | Psychiatry, Pharmacology, Schizophrenia, Neurophysiology, Etiopathogenesis, Memantine, Amantadine |
Texto completo: | Texto completo (Ver HTML) |